![Liam Morgan](https://profiles-cardiff.imgix.net/attachments/2515?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Liam Morgan
Research Associate
- MorganLD1@caerdydd.ac.uk
- +44 29208 79274
- Tŷ McKenzie, Ystafell Floor 6, 30-36 Heol Casnewydd, Caerdydd, CF24 0DE
Trosolwyg
Overview
I am currently the Organisational & Staff Development Officer for Research at Cardiff University, and Programme Manager for the 'Welsh Crucible' programme of personal, professional and leadership development for future research leaders in Wales.
Previously, I have worked as a Research Associate in the Cardiff CLL Research Group and in the Cardiff-China Medical Research Collaborative (CCMRC), both part of the Division of Cancer & Genetics at Cardiff University School of Medicine.
My research has most recently focused on the metastasis of prostate cancer to bone, looking specifically at the factors involved in the osteoblastic phenotype exhibited by prostate cancer, in addition to the interactions between prostate cancer cells and the permissive bone microenvironment that allow secondary tumours to develop and progress at these sites. My research was funded by Cancer Research Wales.
Cyhoeddiad
2019
- Sanders, A. et al. 2019. Importance of activated leukocyte cell adhesion molecule (ALCAM) in prostate cancer progression and metastatic dissemination. Oncotarget 10(59), pp. 6362-6377. (10.18632/oncotarget.27279)
2017
- Feng, Y., Sanders, A. J., Morgan, L. D., Owen, S., Ruge, F., Harding, K. G. and Jiang, W. G. 2017. In vitro significance of SOCS-3 and SOCS-4 and potential mechanistic links to wound healing. Scientific Reports 7(1), article number: 6715. (10.1038/s41598-017-06886-6)
2016
- Feng, Y., Sanders, A., Morgan, L., Harding, K. and Jiang, W. 2016. Potential roles of suppressor of cytokine signaling in wound healing. Regenerative Medicine 11(2), pp. 193-209. (10.2217/rme.16.4)
2012
- Hamilton, E. et al. 2012. Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells. British Journal of Haematology 158(5), pp. 589-599. (10.1111/j.1365-2141.2012.09191.x)
2011
- Evans, B. A. J. et al. 2011. The influence of leptin on trabecular architecture and marrow adiposity in GH-deficient rats. Journal of Endocrinology 208(1), pp. 69-79. (10.1677/JOE-10-0178)
- Pepper, C. J. et al. 2011. Two novel aspirin analogues show selective cytotoxicity in primary chronic lymphocytic leukaemia cells that is associated with dual inhibition of Rel A and COX-2. Cell Proliferation 44(4), pp. 380-390. (10.1111/j.1365-2184.2011.00760.x)
2010
- Pearce, L. et al. 2010. Genetic modification of primary chronic lymphocytic leukemia cells with a lentivirus expressing CD38. Haematologica 95(3), pp. 514-517. (10.3324/haematol.2009.014381)
2009
- Morgan, L. D. et al. 2009. Elevated Src kinase activity attenuates tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biology and Therapy 8(16), pp. 1550-1558. (10.4161/cbt.8.16.8954)
- Hiscox, S. E. et al. 2009. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Research and Treatment 115(1), pp. 57-67. (10.1007/s10549-008-0058-6)
- Hiscox, S. E., Jordan, N. J., Morgan, L. D., Smith, C., Goddard, L., Gee, J. . M. W. and Nicholson, R. 2009. Adverse features of acquired antihormone resistance and their targeting. In: Hiscox, S. E., Gee, J. M. W. and Nicholson, R. eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets. London: Springer, pp. 139-160., (10.1007/978-1-4020-8526-0_8)
2008
- Morgan, L. D., Nicholson, R. and Hiscox, S. 2008. Src as a therapeutic target in breast cancer. Endocrine‚ Metabolic & Immune Disorders - Drug Targets 8(4), pp. 273-278. (10.2174/187153008786848295)
2007
- Hiscox, S. E., Jordan, N. J., Morgan, L. D., Green, T. P. and Nicholson, R. I. 2007. Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clinical & Experimental Metastasis 24(3), pp. 157-167. (10.1007/s10585-007-9065-y)
- Morgan, L. D. 2007. Elevated Src kinase activity accompanies endocrine-resistance in breast cancer and promotes an aggressive cell phenotype. PhD Thesis, Cardiff University.
2006
- Hiscox, S. E., Morgan, L. D., Green, T. and Nicholson, R. 2006. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocrine-Related Cancer 13, pp. S53-S59. (10.1677/erc.1.01297)
- Hiscox, S. E., Morgan, L. D., Green, T. P., Barrow, D., Gee, J. M. W. and Nicholson, R. I. 2006. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast cancer research and treatment 97(3), pp. 263-274. (10.1007/s10549-005-9120-9)
- Hiscox, S. E. et al. 2006. Tamoxifen-resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of [beta]-catenin phosphorylation. International journal of cancer 118(2), pp. 290-301. (10.1002/ijc.21355)
2004
- Hiscox, S. E., Morgan, L. D., Barrow, D., Dutkowski, C. M., Wakeling, A. and Nicholson, R. I. 2004. Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clinical & Experimental Metastasis 21(3), pp. 201-212. (10.1023/B:CLIN.0000037697.76011.1d)
2002
- Morton, M. S., Arisaka, O., Miyake, N., Morgan, L. D. and Evans, B. A. J. 2002. Phytoestrogen concentrations in serum from Japanese men and women over forty years of age. Journal of Nutrition 132(10), pp. 3168-3171.
Adrannau llyfrau
- Hiscox, S. E., Jordan, N. J., Morgan, L. D., Smith, C., Goddard, L., Gee, J. . M. W. and Nicholson, R. 2009. Adverse features of acquired antihormone resistance and their targeting. In: Hiscox, S. E., Gee, J. M. W. and Nicholson, R. eds. Therapeutic Resistance to Anti-Hormonal Drugs in Breast Cancer: New Molecular Aspects and their Potential as Targets. London: Springer, pp. 139-160., (10.1007/978-1-4020-8526-0_8)
Erthyglau
- Sanders, A. et al. 2019. Importance of activated leukocyte cell adhesion molecule (ALCAM) in prostate cancer progression and metastatic dissemination. Oncotarget 10(59), pp. 6362-6377. (10.18632/oncotarget.27279)
- Feng, Y., Sanders, A. J., Morgan, L. D., Owen, S., Ruge, F., Harding, K. G. and Jiang, W. G. 2017. In vitro significance of SOCS-3 and SOCS-4 and potential mechanistic links to wound healing. Scientific Reports 7(1), article number: 6715. (10.1038/s41598-017-06886-6)
- Feng, Y., Sanders, A., Morgan, L., Harding, K. and Jiang, W. 2016. Potential roles of suppressor of cytokine signaling in wound healing. Regenerative Medicine 11(2), pp. 193-209. (10.2217/rme.16.4)
- Hamilton, E. et al. 2012. Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells. British Journal of Haematology 158(5), pp. 589-599. (10.1111/j.1365-2141.2012.09191.x)
- Evans, B. A. J. et al. 2011. The influence of leptin on trabecular architecture and marrow adiposity in GH-deficient rats. Journal of Endocrinology 208(1), pp. 69-79. (10.1677/JOE-10-0178)
- Pepper, C. J. et al. 2011. Two novel aspirin analogues show selective cytotoxicity in primary chronic lymphocytic leukaemia cells that is associated with dual inhibition of Rel A and COX-2. Cell Proliferation 44(4), pp. 380-390. (10.1111/j.1365-2184.2011.00760.x)
- Pearce, L. et al. 2010. Genetic modification of primary chronic lymphocytic leukemia cells with a lentivirus expressing CD38. Haematologica 95(3), pp. 514-517. (10.3324/haematol.2009.014381)
- Morgan, L. D. et al. 2009. Elevated Src kinase activity attenuates tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biology and Therapy 8(16), pp. 1550-1558. (10.4161/cbt.8.16.8954)
- Hiscox, S. E. et al. 2009. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Research and Treatment 115(1), pp. 57-67. (10.1007/s10549-008-0058-6)
- Morgan, L. D., Nicholson, R. and Hiscox, S. 2008. Src as a therapeutic target in breast cancer. Endocrine‚ Metabolic & Immune Disorders - Drug Targets 8(4), pp. 273-278. (10.2174/187153008786848295)
- Hiscox, S. E., Jordan, N. J., Morgan, L. D., Green, T. P. and Nicholson, R. I. 2007. Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clinical & Experimental Metastasis 24(3), pp. 157-167. (10.1007/s10585-007-9065-y)
- Hiscox, S. E., Morgan, L. D., Green, T. and Nicholson, R. 2006. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocrine-Related Cancer 13, pp. S53-S59. (10.1677/erc.1.01297)
- Hiscox, S. E., Morgan, L. D., Green, T. P., Barrow, D., Gee, J. M. W. and Nicholson, R. I. 2006. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast cancer research and treatment 97(3), pp. 263-274. (10.1007/s10549-005-9120-9)
- Hiscox, S. E. et al. 2006. Tamoxifen-resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of [beta]-catenin phosphorylation. International journal of cancer 118(2), pp. 290-301. (10.1002/ijc.21355)
- Hiscox, S. E., Morgan, L. D., Barrow, D., Dutkowski, C. M., Wakeling, A. and Nicholson, R. I. 2004. Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839). Clinical & Experimental Metastasis 21(3), pp. 201-212. (10.1023/B:CLIN.0000037697.76011.1d)
- Morton, M. S., Arisaka, O., Miyake, N., Morgan, L. D. and Evans, B. A. J. 2002. Phytoestrogen concentrations in serum from Japanese men and women over forty years of age. Journal of Nutrition 132(10), pp. 3168-3171.
Gosodiad
- Morgan, L. D. 2007. Elevated Src kinase activity accompanies endocrine-resistance in breast cancer and promotes an aggressive cell phenotype. PhD Thesis, Cardiff University.
Ymchwil
Ymchwil
Ar ôl graddio gyda BSc mewn Biocemeg o Brifysgol Warwick ymunais â'r Adran Iechyd Plant yn Ysgol Meddygaeth Prifysgol Caerdydd lle ymchwiliais i rinweddau amddiffynnol ffytoestrogenau wrth ddatblygu canser y fron. O'r fan hon symudais i leoliad mwy diwydiannol, gan ennill profiad gwerthfawr yn gweithio fel uwch aelod o'r adran Cromatograffaeth yn y Gwasanaethau Bio-glinigol, CRO lleol sydd wedi'i leoli yng Nghaerdydd.
Dychwelais i'r byd academaidd yn 2002 pan ymunais â'r tîm yng Nghanolfan Ymchwil Canser Tenovus (Grŵp Ffarmacoleg Foleciwlaidd Canser y Fron erbyn hyn) yn Ysgol Fferylliaeth a Gwyddorau Fferyllol Caerdydd. Roedd fy ngwaith yn archwilio rôl kinasau teulu Src yn y potensial metastatig cynyddol sy'n gysylltiedig â chanser y fron sy'n gwrthsefyll Tamoxifen. Yn ddiweddarach daeth y pwnc hwn yn ganolbwynt fy astudiaethau ar ôl i mi benderfynu ymgymryd â PhD gyda'r grŵp; roedd y data a gynhyrchais yn awgrymu rôl bosibl i Src nid yn unig wrth ddatblygu ffenoteip metastatig ond hefyd wrth gaffael a chynnal ymwrthedd Tamoxifen ei hun.
Ar ôl cwblhau fy PhD dychwelais i Ysgol Meddygaeth Prifysgol Caerdydd lle ymunais â Grŵp Ymchwil Lewcemia Lymffocytig Cronig Caerdydd (CLL). Yma, archwiliodd fy mhrosiect y ffactorau achosol sy'n gysylltiedig â datblygu CLL ymosodol, gan ganolbwyntio ar rôl bosibl y marciwr prognostig CD38. Datblygodd y prosiect yn raddol dros amser a newidiodd fy niddordebau tuag at reoleiddio mynegiant CD38 mewn celloedd CLL cynradd, gan ganolbwyntio ar gyfranogiad signalau allgellog a dderbyniwyd o'r micro-amgylchedd lymffoid a rôl llwybrau signalau NF-kB.
Yn 2015 ymunais â Chydweithfa Ymchwil Feddygol Caerdydd-Tsieina (CCMRC) yn yr Ysgol Meddygaeth er mwyn dychwelyd at fy mhrif ddiddordeb ymchwil, sef metastasis tiwmorau solet. Mae fy ymchwil gyfredol yn canolbwyntio ar fetastasis canser y prostad i asgwrn, gan edrych yn benodol ar y ffactorau sy'n gysylltiedig â'r ffenoteip osteoblastig a arddangoswyd gan ganser y prostad, yn ogystal â'r rhyngweithio rhwng celloedd canser y prostad a'r micro-amgylchedd esgyrn caniataol sy'n caniatáu i diwmorau eilaidd ddatblygu a symud ymlaen ar y safleoedd hyn.
Meysydd arbenigedd technegol
- Profion ymddygiad celloedd (adlyniad, ymfudo, goresgyniad ac amlhau)
- Cromatodin immunoprecipitation (ChIP)
- Cymesuredd llif
- Gene up-regulation/knock-out
- Immunocytochemistry
- Diwylliant celloedd in vitro (llinellau cynradd a cell)
- PCR / qPCR
- SDS PAGE/Western potelu
Addysgu
Addysgu
- Goruchwylio myfyrwyr Prosiect Intercalated Lab ar gyfer y Rhaglen Gradd Intercalated.
- Hyfforddi, mentora a goruchwylio myfyrwyr ôl-raddedig (MRes, MD, PhD) a SSC.
- Mentor Academaidd i MB BCh myfyrwyr meddygol israddedig.
Ymgysylltu â'r Cyhoedd
- Cyfranogwr mynych yn y rhaglen 'Gwyddoniaeth mewn Iechyd yn Fyw' a gynhelir gan Ysgol Meddygaeth Prifysgol Caerdydd.
- Cyfrannwr gweithredol i ymchwilio i ddiwrnodau agored a gynhelir ar gyfer aelodau'r cyhoedd gan elusennau fel CRUK.
Bywgraffiad
Education and Qualifications
2008: PhD (Cancer Pharmacology) Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff UK
- Thesis: “Elevated Src Kinase activity accompanies endocrine-resistance in breast cancer and promotes an aggressive cell phenotype”
1996: Biochemistry BSc (Hons) Warwick University, Coventry, Warwickshire, UK
Career Overview
- 2017 - Present Organisational and Staff Development Officer (Research), Cardiff University, Cardiff, UK
- 2017 - Present Welsh Crucible Programme Manager, Cardiff University, Cardiff, UK
- 2015 – 2016: Research Associate, CCMRC, Cardiff University School of Medicine, Cardiff, UK
- 2008 – 2015: Research Associate, Cardiff CLL Research Group, Cardiff University School of Medicine, Cardiff, UK
- 2007 – 2008: Research Technician, Dept. of Child Health, Cardiff University School of Medicine, Cardiff, UK
- 2003 – 2007: PhD Studentship, Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff UK
Honours and Awards
CUKC Poster Scholar 2015 - China-UK Cancer Conference, Cardiff, UK (July 2015)
- “Identification of an NF-kB-Dependent CD38 Positive Feedback Loop in Chronic Lymphocytic Leukaemia (CLL)”
Postgraduate Researcher Poster Prize - Cardiff School of Pharmacy and Pharmaceutical Sciences Postgraduate Research Day, Cardiff, UK (March 2005)
- “Elevated Src kinase activity promotes an aggressive tumour cell phenotype in endocrine-resistant breast cancer”
Speaking Engagements
- 2016 – Invited speaker at China-UK Cancer Conference 2016 (Beijing, China)
- 2016 – CCMRC Winter Academic Meeting (Cardiff, UK)
- 2014 – European NF-kB Workshop (Pitlochry, Scotland, UK)
- 2012 – Site visit for Bloodwise (formerly LLR) grant application (Cardiff University School of Medicine, Cardiff, UK)
- 2011 – Division of Cancer & Genetics Seminar (Cardiff University School of Medicine, Cardiff, UK)
- 2010 – Division of Infection & Immunity Seminar (Cardiff University School of Medicine, Cardiff, UK)
- 2009 – Division of Cancer & Genetics (Haematology) Seminar (Cardiff University School of Medicine, Cardiff, UK)